BETA
BETA
Gilead Sciences
GILD73
$77.01arrow_drop_up0.65%$0.50
S&P500
GILD73
$77.01
arrow_drop_up0.65%Performance History
| Key Stats | |
|---|---|
| Open | $76.03 |
| Prev. Close | $76.51 |
| EPS | 0.36 |
| Next Earnings Date | Sep 26, 2024 |
| LOW | HIGH | |
|---|---|---|
| Day Range | 75.75 | 78.29 |
| 52 Week Range | 62.07 | 87.87 |
| Ratios | |
|---|---|
| EPS | 0.36 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
Correlated Companies
About Gilead Sciences (GILD)
- Sector
- Healthcare
- Industry
- Drug Manufacturers—General
- CEO
- Mr. Daniel P. O'Day
- Headquarters
- Foster City
- Employees
- 17000
- Exchange
- NASDAQ
Keep an eye on Gilead Sciences
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Gilead Sciences 's (GILD) price per share?
The current price per share for Gilead Sciences (GILD) is $77.01. The stock has seen a price change of $0.5 recently, indicating a 0.65% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Gilead Sciences (GILD)?
For Gilead Sciences (GILD), the 52-week high is $87.87, which is 14.1% from the current price. The 52-week low is $62.07, the current price is 24.07% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Gilead Sciences (GILD) a growth stock?
Gilead Sciences (GILD) has shown an average price growth of 0.41% over the past three years. It has received a score of 61 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Gilead Sciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Gilead Sciences (GILD) stock price performance year to date (YTD)?
As of the latest data, Gilead Sciences (GILD) has a year-to-date price change of -7.48%. Over the past month, the stock has experienced a price change of 10.63%. Over the last three months, the change has been 17.99%. Over the past six months, the figure is -4.01%. Looking at a longer horizon, the five-year price change stands at 16.12%.
help
Is Gilead Sciences (GILD) a profitable company?
Gilead Sciences (GILD) has a net income of $5.61B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 34.43% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $27.12B, although specific revenue growth data is currently not available. The gross profit is $27.12B. Operating income is noted at $7.6B. Furthermore, the EBITDA is $9.64B.
help
What is the market capitalization of Gilead Sciences (GILD)?
Gilead Sciences (GILD) has a market capitalization of $94.45B. The average daily trading volume is 7.03M, indicating the stock's liquidity and investor engagement.
News
HIV
CARDIOVASCULAR DISEASE
ABACAVIR
ANTIRETROVIRAL TREATMENTS
7/23/2024ACTG Presents Data Analysis at AIDS 2024 Showing - GlobeNewswire
GILEAD SCIENCES
ANALYST RATINGS
PRICE TARGETS
7/22/2024Breaking Down Gilead Sciences: 10 Analysts Share Their Views - Benzinga
DIVIDEND STOCKS
PASSIVE INCOME
AT&T
GILEAD SCIENCES
JPMORGAN EQUITY PREMIUM INCOME ETF
7/17/2024Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays - The Motley Fool
DIVIDEND GROWTH STOCKS
ABBVIE
AMGEN
GILEAD SCIENCES
7/14/20243 Dividend Growth Stocks to Buy and Hold - The Motley Fool
IOVANCE BIOTHERAPEUTICS
BIOTECH
CANCER TREATMENTS
MILLIONAIRE-MAKER STOCK
7/14/2024Is Iovance Biotherapeutics a Millionaire Maker? - The Motley Fool
ANTIBODY DRUG CONJUGATES
CANCER
MARKET GROWTH
MARKET SHARE
7/12/2024Antibody Drug Conjugates Market Insights 2018-2023 and - GlobeNewswire
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.